Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,793 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
Matsuoka O, Ujiie M, Kikuchi H, Otake S, Chansinghakul D, Inoue T, Varghese K, Sirisuphmitr N, Hashiguchi T, Zambrano B, Nakama T, Frago C, Jordanov E, Dhingra MS. Matsuoka O, et al. Among authors: inoue t. Jpn J Infect Dis. 2023 May 24;76(3):174-182. doi: 10.7883/yoken.JJID.2022.272. Epub 2023 Jan 31. Jpn J Infect Dis. 2023. PMID: 36724939 Free article. Clinical Trial.
Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
Sanchez L, Matsuoka O, Inoue S, Inoue T, Meng Y, Nakama T, Kato K, Pandey A, Chang LJ. Sanchez L, et al. Among authors: inoue t, inoue s. Hum Vaccin Immunother. 2020 Apr 2;16(4):858-866. doi: 10.1080/21645515.2019.1677437. Epub 2019 Nov 19. Hum Vaccin Immunother. 2020. PMID: 31634025 Free PMC article. Clinical Trial.
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
Terauchi Y, Nakama T, Spranger R, Amano A, Inoue T, Niemoeller E. Terauchi Y, et al. Among authors: inoue t. Diabetes Obes Metab. 2020 Sep;22 Suppl 4:14-23. doi: 10.1111/dom.14036. Diabetes Obes Metab. 2020. PMID: 32291880 Clinical Trial.
Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
Sanchez L, Nakama T, Nagai H, Matsuoka O, Inoue S, Inoue T, Shrestha A, Pandey A, Chang LJ, De Bruijn I; QHD00010 Study Group. Sanchez L, et al. Among authors: inoue t, inoue s. Vaccine. 2023 Apr 6;41(15):2553-2561. doi: 10.1016/j.vaccine.2023.02.071. Epub 2023 Mar 10. Vaccine. 2023. PMID: 36906404 Free article. Clinical Trial.
Clinical characteristics and short-term outcomes of patients with critical acute pulmonary embolism requiring extracorporeal membrane oxygenation: from the COMMAND VTE Registry-2.
Takabayashi K, Yamashita Y, Morimoto T, Chatani R, Kaneda K, Nishimoto Y, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Tsuji S, Oi M, Takada T, Otsui K, Sakamoto J, Ogihara Y, Inoue T, Usami S, Chen PM, Togi K, Koitabashi N, Hiramori S, Doi K, Mabuchi H, Tsuyuki Y, Murata K, Nakai H, Sueta D, Shioyama W, Dohke T, Nishikawa R, Ono K, Kimura T; COMMAND VTE Registry-2 Investigators. Takabayashi K, et al. Among authors: inoue t. J Intensive Care. 2024 Nov 5;12(1):45. doi: 10.1186/s40560-024-00755-x. J Intensive Care. 2024. PMID: 39497225
Reduced 18F-FDG uptake in the basal interventricular septum as a predictor of fatal ventricular arrhythmic events in patients with cardiac sarcoidosis.
Takeuchi K, Suzuki H, Takanami K, Ota H, Tanaka Y, Fujishima F, Watanabe H, Susukita K, Inoue T, Arai M, Hayashi H, Nochioka K, Takahama H, Suzuki T, Takase K, Yasuda S. Takeuchi K, et al. Among authors: inoue t. Int J Cardiol. 2024 Oct 25:132686. doi: 10.1016/j.ijcard.2024.132686. Online ahead of print. Int J Cardiol. 2024. PMID: 39490748
Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case.
Kuwata T, Kaku Y, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Uraki R, Okazaki K, Minami R, Nagasaki Y, Nagashima M, Yoshida I, Sadamasu K, Yoshimura K, Ito M, Kiso M, Yamayoshi S, Imai M, Ikeda T, Sato K, Toyoda M, Ueno T, Inoue T, Tanaka Y, Kimura KT, Hashiguchi T, Sugita Y, Noda T, Morioka H, Kawaoka Y, Matsushita S; Genotype to Phenotype Japan (G2P-Japan) Consortium. Kuwata T, et al. Among authors: inoue t. EBioMedicine. 2024 Nov 1;110:105439. doi: 10.1016/j.ebiom.2024.105439. Online ahead of print. EBioMedicine. 2024. PMID: 39488016 Free article.
11,793 results
You have reached the last available page of results. Please see the User Guide for more information.